Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

Najib Lamharzi, Andrew V. Schally, M. Koppán

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

In previous studies, we showed that LH-RH antagonist Cetrorelix inhibits the growth of DU-145 and PC-3 human androgen-independent prostate cancers in nude mice. To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer with Cetrorelix at a dose of 100 μg/animal subcutaneously (s.c.) once a day. Tumor growth, serum and tumor levels of IGF-I and -II as well as the mRNA expression of IGF-I and -II in tumors were evaluated. After 8 weeks of treatment, final volume and weight of DU-145 tumors in mice treated with Cetrorelix were significantly decreased compared with controls and serum IGF-1 showed a significant reduction. Therapy with Cetrorelix also reduced by 84% the levels of IGF-II in DU-145 tumor tissue compared with controls, but did not affect the concentration of IGF-I. RT-PCR analyses revealed a high expression of mRNA for IGF-II, but not for IGF-I in DU-145 tumors. Treatment with Cetrorelix decreased the expression of IGF-II mRNA by 78% (p

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalRegulatory Peptides
Volume77
Issue number1-3
DOIs
Publication statusPublished - Oct 16 1998

Fingerprint

Hormone Antagonists
Insulin-Like Growth Factor II
Nude Mice
Gonadotropin-Releasing Hormone
Androgens
Tumors
Prostate
Insulin-Like Growth Factor I
Carcinoma
Messenger RNA
Growth
Neoplasms
Prostatic Neoplasms
Bearings (structural)
Serum
Heterografts
cetrorelix
Animals
Tissue
Weights and Measures

Keywords

  • DU-145 human androgen-independent prostate cancers
  • Insulin-like growth factor II (IGF-II)
  • Luteinizing hormone-releasing hormone antagonist (LH-RH)
  • mRNA suppression

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Neuroscience(all)

Cite this

@article{2142f112103148759046a74499229682,
title = "Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors",
abstract = "In previous studies, we showed that LH-RH antagonist Cetrorelix inhibits the growth of DU-145 and PC-3 human androgen-independent prostate cancers in nude mice. To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer with Cetrorelix at a dose of 100 μg/animal subcutaneously (s.c.) once a day. Tumor growth, serum and tumor levels of IGF-I and -II as well as the mRNA expression of IGF-I and -II in tumors were evaluated. After 8 weeks of treatment, final volume and weight of DU-145 tumors in mice treated with Cetrorelix were significantly decreased compared with controls and serum IGF-1 showed a significant reduction. Therapy with Cetrorelix also reduced by 84{\%} the levels of IGF-II in DU-145 tumor tissue compared with controls, but did not affect the concentration of IGF-I. RT-PCR analyses revealed a high expression of mRNA for IGF-II, but not for IGF-I in DU-145 tumors. Treatment with Cetrorelix decreased the expression of IGF-II mRNA by 78{\%} (p",
keywords = "DU-145 human androgen-independent prostate cancers, Insulin-like growth factor II (IGF-II), Luteinizing hormone-releasing hormone antagonist (LH-RH), mRNA suppression",
author = "Najib Lamharzi and Schally, {Andrew V.} and M. Kopp{\'a}n",
year = "1998",
month = "10",
day = "16",
doi = "10.1016/S0167-0115(98)00119-0",
language = "English",
volume = "77",
pages = "185--192",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors

AU - Lamharzi, Najib

AU - Schally, Andrew V.

AU - Koppán, M.

PY - 1998/10/16

Y1 - 1998/10/16

N2 - In previous studies, we showed that LH-RH antagonist Cetrorelix inhibits the growth of DU-145 and PC-3 human androgen-independent prostate cancers in nude mice. To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer with Cetrorelix at a dose of 100 μg/animal subcutaneously (s.c.) once a day. Tumor growth, serum and tumor levels of IGF-I and -II as well as the mRNA expression of IGF-I and -II in tumors were evaluated. After 8 weeks of treatment, final volume and weight of DU-145 tumors in mice treated with Cetrorelix were significantly decreased compared with controls and serum IGF-1 showed a significant reduction. Therapy with Cetrorelix also reduced by 84% the levels of IGF-II in DU-145 tumor tissue compared with controls, but did not affect the concentration of IGF-I. RT-PCR analyses revealed a high expression of mRNA for IGF-II, but not for IGF-I in DU-145 tumors. Treatment with Cetrorelix decreased the expression of IGF-II mRNA by 78% (p

AB - In previous studies, we showed that LH-RH antagonist Cetrorelix inhibits the growth of DU-145 and PC-3 human androgen-independent prostate cancers in nude mice. To investigate the mechanisms involved, we treated male nude mice bearing xenografts of DU-145 human androgen-independent prostate cancer with Cetrorelix at a dose of 100 μg/animal subcutaneously (s.c.) once a day. Tumor growth, serum and tumor levels of IGF-I and -II as well as the mRNA expression of IGF-I and -II in tumors were evaluated. After 8 weeks of treatment, final volume and weight of DU-145 tumors in mice treated with Cetrorelix were significantly decreased compared with controls and serum IGF-1 showed a significant reduction. Therapy with Cetrorelix also reduced by 84% the levels of IGF-II in DU-145 tumor tissue compared with controls, but did not affect the concentration of IGF-I. RT-PCR analyses revealed a high expression of mRNA for IGF-II, but not for IGF-I in DU-145 tumors. Treatment with Cetrorelix decreased the expression of IGF-II mRNA by 78% (p

KW - DU-145 human androgen-independent prostate cancers

KW - Insulin-like growth factor II (IGF-II)

KW - Luteinizing hormone-releasing hormone antagonist (LH-RH)

KW - mRNA suppression

UR - http://www.scopus.com/inward/record.url?scp=0032538353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032538353&partnerID=8YFLogxK

U2 - 10.1016/S0167-0115(98)00119-0

DO - 10.1016/S0167-0115(98)00119-0

M3 - Article

VL - 77

SP - 185

EP - 192

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 1-3

ER -